Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Gastric Cancer
Interventions
DRUG

Docetaxel

Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.

DRUG

Cisplatin

Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.

DRUG

Capecitabine

Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).

RADIATION

Radiation

At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.

DRUG

Capecitabine

Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).

Trial Locations (8)

Unknown

University Hospital of Crete Dept of Medical Oncology, Heraklion

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

General Hospital of Larissa Dept of Medical Oncology, Larissa

"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Piraeus

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER